Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Reshaping a Frontotemporal Dementia (FTD) Disease Market: Regulatory Consulting, Drug Pricing Strategies, Clinical Viewpoints, and Pipeline Assessment | Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

12 Oct, 2023, 16:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 12, 2023 /PRNewswire/ -- Frontotemporal Dementia (FTD) is a rare neurological disorder which is progressive in nature. It leads to a constant degeneration of nerve cells (neurons) in these brain regions, leading to a decline in a person's ability to control their behavior, emotions, and language. According to an epidemiology study by NIH, 15-22 individuals out of 100,000 are diagnosed with this disease.


Frontotemporal disorder primarily impacts the frontal and temporal lobes of the brain. These lobes are responsible for cognitive functions like personality, behavioral variant, language, and social skills. It is a subtype of dementia and has some distinct features. It is worth noting that FTD can occur before the designated age for dementia. In other words, the onset of FTD can occur in individuals as early as their 40s and 50s, making it a relatively young-onset dementia.

Price and Market Access

The Market Competitors Listed Below are Revolutionizing Healthcare with Innovative Diagnostic Inventions:

  • GE Healthcare
  • Siemens Healthineers
  • Philips Healthcare
  • Hitachi, Ltd.
  • Toshiba Corporation
  • Others
  • AbbVie
  • Otsuka America Pharmaceutical, Inc.
  • Pfizer
  • AstraZeneca
  • Eli Lily & Company
  • Others

Learn More About the FDA NDA & BLA Approval (NME) Drugs for Frontotemporal Dementia (FTD) Disease @
https://www.diseaselandscape.com/requestsample/postid/93

Disease Landscape Insights has been a forefront when it comes to rare disease research & development. It has been helping the Frontotemporal dementia     Market players with drug development, treatment gaps identification, clinical trial feasibility analysis, retail drug price insights, pricing reimbursement, price and market access, and disease landscape, among others. It also empowers them with regulatory insights, product launch services, pharma consulting services, new product launch services, product portfolio extension, and post launch strategies, among others.

Causes and Symptoms:

This disease is mainly a result of genetic causes.  Apart from that, environmental factors, neuroinflammation, protein accumulation, and combination of other factors.

Major symptoms of this ailment are behavioural changes, motor symptoms, emotional changes, language difficulties, and loss of insight. FTD brain symptoms can get severe if not treated on time. This disease also leads to the onset of Aphasia, a language disorder. It is advisable to not ignore the early signs of FTD.

Diagnosis And Treatment:

FTD diagnosis involves clinical assessment, brain imaging tests, neuropsychological testing, genetic testing, cerebrospinal fluid analysis, along with neurological and psychiatric evaluation. Diagnosing FTD can be a stretchy and complicated process due to the similarity of its symptoms to other neurological disorders.

Treatment of FTD includes the administration of drugs with FDA EMA approved indications like antidepressants or mood stabilizers. These may help manage behavioral and emotional changes, while cholinesterase inhibitors may be used to address cognitive symptoms in some cases.

Besides, language and speech therapy, occupational therapy, and supportive care, among others are also recommended in the treatment procedure.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @
https://www.diseaselandscape.com/checkout?report_id=93

Final Words:

FTD is a complex neurodegenerative condition characterized by cognitive and behavioral symptoms. DLI has been offering extensive frontotemporal dementia consulting services to the players with an aim to solidify their position in this vertical. Regulatory consulting services offered by DLI plays a crucial role in expediting the development and approval of potential treatments, ensuring that promising therapies can reach patients more quickly. It also offers effective drug launch strategies that are vital for successful market penetration, considering factors like pricing, market analysis, and awareness campaigns. Additionally, precise clinical trial assessments are essential to design trials that yield robust data, optimizing the development of new FTD therapies.  A multifaceted approach that leverages regulatory expertise, strategic drug launches, and meticulous clinical trial planning can significantly impact the FTD landscape, potentially providing hope for patients and their families. DLI is indeed transforming the FTD disease management vertical, creating a ray of hope for patients and their caregivers. By joining hands with the players, it has emerged as an indispensable tool in the process of diagnostic and treatment entities development against this rare neurological disorder.

Browse Through More Neurodegenerative Disorders Research Reports.

Related Reports:

We provide specialist advice on all elements of Huntington's Disease (HD), including FDA/EMA-approved medications, market access, pricing tactics, reimbursement, and epidemiology studies.

Examining the Impact of AI on Radiology: AI Applications in Medical Imaging

Addressing Ethical Considerations in AI Healthcare: Insights and Strategies

Top cancer-related causes of death

Paxlovid is recognized as a COVID-19 Breakthrough Therapy with Emergency Use Authorization.

The Top 5 Monkeypox Research Companies and Monkeypox

How Technology is Revolutionizing the Entire Drug Discovery Sector: The Power of Tech Innovation

Fighting Lung Cancer: Causes, Treatment, Research, and Leading Companies

Money Is Important: Boosting Clinical Trial Revenue Strategies by Resolving CRO Issues

Miebo: A Hopeful New Method for Treating Dry Eye Disease

Qalsody: A Revolutionary Drug from Biogen Inc.

How Can Clinical Trial Ancillary Management Be Improved to Enhance Research Outcomes?

Introducing the Global Market for Monkeypox Disease: Seizing Chances for a Healthier Future

Overcoming Obstacles by Presenting Hope in Lupus Disease Research

Diabetes Treatment Without Needles: Diagnostic Advances and Market Change

Manufacturing Barriers for Early Pancreatic Cancer Detection Kit Manufacturers: Understanding the Maze

Creating the Future of Pneumonia Treatment Options is boosting market growth.

A Game-Changer for the Management of Patients with Ovarian Cancer: Inhibitors of PARP

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us: 

Disease Landscape Insights LLP 
6th Floor, Sr No.207, Office A H 6070 Phase 1 
Solitaire Business Hub, Viman Nagar 
Pune, Maharashtra, 411014.
Sales Contact: +44-2038074155 
Asia Office Contact: +917447409162
Email: ajay@diseaselandscape.com
Email: vishal@diseaselandscape.com
Blog: https://www.diseaselandscape.com/blogs
Case Study: https://www.diseaselandscape.com/casestudies    
Pharma consulting Services 
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.